Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

0.8059
-0.0584-6.76%
Post-market: 0.81000.0041+0.51%19:56 EDT
Volume:154.04K
Turnover:125.25K
Market Cap:2.71M
PE:-0.05
High:0.8469
Open:0.8410
Low:0.7900
Close:0.8643
52wk High:524.00
52wk Low:0.7900
Shares:3.37M
Float Shares:3.37M
Volume Ratio:0.72
T/O Rate:4.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.8013
EPS(LYR):-303.4772
ROE:-106.98%
ROA:-53.08%
PB:0.21
PE(LYR):0.00

Loading ...

BRIEF-Clearmind Medicine Announces 1-For-10 Reverse Share Split

Reuters
·
May 19

Clearmind Medicine Announces 1-for-10 Reverse Share Split

THOMSON REUTERS
·
May 19

Clearmind Medicine to sell USD 600,000 convertible notes at 90% of face value

Reuters
·
May 19

Clearmind Medicine signs new research agreement with Yissum Research Development

TIPRANKS
·
May 18

Clearmind signs preclinical study of MEAI with tirzepatide in obese mice

Reuters
·
May 18

Clearmind Medicine Signs Agreement to Examine Meai in Combination and Sequencing With Tirzepatide Against Blockbuster Glp-1 Medications

THOMSON REUTERS
·
May 18

Clearmind Medicine CEO DR. Adi Zuloff-Shani Named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.c.

THOMSON REUTERS
·
May 15

Clearmind doses 2 more patients in CMND-100 alcohol use disorder trial cohort 4

Reuters
·
May 12

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants NOW Treated in Ongoing Phase I/Iia Trial of Cmnd-100 for Alcohol Use Disorder

THOMSON REUTERS
·
May 12

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

GlobeNewswire
·
May 12

Clearmind Medicine to host “Inside MEAI” webinar on CMND-100 trial data

Reuters
·
May 11

Clearmind Medicine Announces “Inside Meai” Webinar Featuring New Insights From Cmnd-100 Psychedelic Clinical Trial

THOMSON REUTERS
·
May 11

BRIEF-Clearmind Medicine Announces Filing Of European Patent Application For Novel Psychedelic Compounds For The Treatment Of Ptsd

Reuters
·
May 05

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of Ptsd

THOMSON REUTERS
·
May 05

Clearmind names Hila Kiron-Revach board chair after Amitay Weiss steps down

Reuters
·
May 01

Clearmind evaluates MEAI for FDA breakthrough therapy designation in alcohol use disorder trial

Reuters
·
Apr 27

Clearmind Medicine Inc - Has Not Submitted or Received FDA Breakthrough Therapy Designation for Meai

THOMSON REUTERS
·
Apr 27

Clearmind Medicine issues $2.7 million convertible notes at 10% discount

Reuters
·
Apr 21

Clearmind welcomes Trump executive order speeding FDA review of breakthrough psychedelic therapies

Reuters
·
Apr 21

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM

Reuters
·
Apr 20